
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2061846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhibitory effects of sesquiterpene lactones from the Indonesian marine sponge Lamellodysidea cf. herbacea on bone morphogenetic protein-induced osteoblastic differentiation. Bioorganic and Medicinal Chemistry Letters, 2021, 35, 127783.	2.2	7
2	Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. Bioorganic and Medicinal Chemistry Letters, 2021, 38, 127858.	2.2	5
3	Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders. Biomedicines, 2021, 9, 736.	3.2	7
4	Fibrodysplasia ossificans progressiva: Review and research activities in Japan. Pediatrics International, 2020, 62, 3-13.	0.5	11
5	Screening for Small Molecule Inhibitors of BMP-Induced Osteoblastic Differentiation from Indonesian Marine Invertebrates. Marine Drugs, 2020, 18, 606.	4.6	5
6	Penicillic Acid Congener, a New Inhibitor of BMP-Induced Alkaline Phosphatase Activity in Myoblasts, Produced by the Fungus Penicillium sp. BF-0343. Natural Product Communications, 2020, 15, 1934578X2094265.	0.5	1
7	Smad4-dependent transforming growth factor-Ĵ² family signaling regulates the differentiation of dental epithelial cells in adult mouse incisors. Bone, 2020, 137, 115456.	2.9	4
8	Design of primers for direct sequencing of nine coding exons in the human ACVR1 gene. Bone, 2020, 138, 115469.	2.9	4
9	Functional characterization of a unique mutant of ALK2, p.K400E, that is associated with a skeletal disorder, diffuse idiopathic skeletal hyperostosis. Bone, 2020, 137, 115410.	2.9	8
10	A new diketopiperazine-like inhibitor of bone morphogenetic protein-induced osteoblastic differentiation produced by marine-derived Aspergillus sp. BFM-0085. Journal of Antibiotics, 2020, 73, 554-558.	2.0	12
11	Dual usage of a stage-specific fluorescent reporter system based on a helper-dependent adenoviral vector to visualize osteogenic differentiation. Scientific Reports, 2019, 9, 9705.	3.3	3
12	Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders. Bone, 2018, 111, 101-108.	2.9	29
13	Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva. Bone, 2018, 109, 241-250.	2.9	33
14	Discovery of Heterotopic Bone-Inducing Activity in Hard Tissues and the TGF-Î <sup>2</sup> Superfamily. International Journal of Molecular Sciences, 2018, 19, 3586.	4.1	10
15	Recent Topics in Fibrodysplasia Ossificans Progressiva. Endocrinology and Metabolism, 2018, 33, 331.	3.0	23
16	BMPR2 inhibits activin- and BMP-signaling via wild type ALK2. Journal of Cell Science, 2018, 131, .	2.0	42
17	A potential novel option for cancer immunotherapy - TLR7 stimulation inhibits malignant melanoma bone invasion. Oncotarget, 2018, 9, 31792-31792.	1.8	2
18	Novel In Vitro Assay Models to Study Osteogenesis and Chondrogenesis for Human Skeletal		0

Disorders. , 2017, , 113-126.

#	Article	IF	CITATIONS
19	Scopranones with Two Atypical Scooplike Moieties Produced by <i>Streptomyces</i> sp. BYK-11038. Organic Letters, 2017, 19, 5980-5983.	4.6	16
20	Molecular mechanisms for activation of mutant activin receptor-like kinase 2 in fibrodysplasia ossificans progressiva. Journal of Oral Biosciences, 2017, 59, 121-126.	2.2	1
21	Bone Morphogenetic Proteins. Cold Spring Harbor Perspectives in Biology, 2016, 8, a021899.	5.5	356
22	A Door Opens for Fibrodysplasia Ossificans Progressiva. Trends in Biochemical Sciences, 2016, 41, 119-121.	7.5	12
23	Phenotypic differences of patients with fibrodysplasia ossificans progressive due to p.Arg258Ser variants of ACVR1. Human Genome Variation, 2015, 2, 15055.	0.7	9
24	Involvement of PRIP (Phospholipase Câ€Related But Catalytically Inactive Protein) in BMPâ€Induced Smad Signaling in Osteoblast Differentiation. Journal of Cellular Biochemistry, 2015, 116, 2814-2823.	2.6	4
25	Mutant Activin-Like Kinase 2 in Fibrodysplasia Ossificans Progressiva are Activated via T203 by BMP Type Il Receptors. Molecular Endocrinology, 2015, 29, 140-152.	3.7	25
26	Bone morphogenetic protein-induced heterotopic bone formation: What have we learned from the history of a half century?. Japanese Dental Science Review, 2015, 51, 42-50.	5.1	11
27	Inhibition of bone morphogenetic protein-induced osteoblast differentiation. Journal of Oral Biosciences, 2015, 57, 179-184.	2.2	3
28	Radiographic characteristics of the hand and cervical spine in fibrodysplasia ossificans progressiva. Intractable and Rare Diseases Research, 2014, 3, 46-51.	0.9	10
29	Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2. Biochemical and Biophysical Research Communications, 2014, 455, 347-352.	2.1	8
30	Expression of TLE3 by bone marrow stromal cells is regulated by canonical Wnt signaling. FEBS Letters, 2014, 588, 614-619.	2.8	21
31	5-Prenyltryptophol, a new inhibitor of bone morphogenetic protein-induced alkaline phosphatase expression in myoblasts, produced by Streptomyces colinus subsp. albescens HEK608. Journal of Antibiotics, 2014, 67, 589-591.	2.0	9
32	Identification of a novel bone morphogenetic protein (BMP)-inducible transcript, BMP-inducible transcript-1, by utilizing the conserved BMP-responsive elements in the Id genes. Journal of Bone and Mineral Metabolism, 2013, 31, 34-43.	2.7	19
33	The unique activity of bone morphogenetic proteins in bone: a critical role of the Smad signaling pathway. Biological Chemistry, 2013, 394, 703-714.	2.5	56
34	TLE3, transducing-like enhancer of split 3, suppresses osteoblast differentiation of bone marrow stromal cells. Biochemical and Biophysical Research Communications, 2013, 438, 205-210.	2.1	29
35	Accumulation of p100, a Precursor of NF-κB2, Enhances Osteoblastic Differentiation <i>in Vitro</i> and Bone Formation <i>in Vivo</i> in <i>aly/aly</i> Mice. Molecular Endocrinology, 2012, 26, 414-422.	3.7	25
36	Recent topics in fibrodysplasia ossificans progressiva. Journal of Oral Biosciences, 2012, 54, 119-123.	2.2	11

3

#	Article	IF	CITATIONS
37	Fungal pyrrolidine-containing metabolites inhibit alkaline phosphatase activity in bone morphogenetic protein-stimulated myoblastoma cells. Acta Pharmaceutica Sinica B, 2012, 2, 23-27.	12.0	21
38	Interaction of Tmem119 and the bone morphogenetic protein pathway in the commitment of myoblastic into osteoblastic cells. Bone, 2012, 51, 158-167.	2.9	35
39	Trichocyalides A and B, new inhibitors of alkaline phosphatase activity in bone morphogenetic protein-stimulated myoblasts, produced by Trichoderma sp. FKI-5513. Journal of Antibiotics, 2012, 65, 565-569.	2.0	16
40	Role of Smad phosphatases in BMP-Smad signaling axis-induced osteoblast differentiation. Journal of Oral Biosciences, 2012, 54, 73-78.	2.2	10
41	Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice. Journal of Bone and Mineral Metabolism, 2012, 31, 26-33.	2.7	17
42	BMP3 Suppresses Osteoblast Differentiation of Bone Marrow Stromal Cells via Interaction with Acvr2b. Molecular Endocrinology, 2012, 26, 87-94.	3.7	99
43	Identification and functional analysis of Zranb2 as a novel Smadâ€binding protein that suppresses BMP signaling. Journal of Cellular Biochemistry, 2012, 113, 808-814.	2.6	15
44	A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochemical and Biophysical Research Communications, 2011, 407, 213-218.	2.1	47
45	Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads. Biochemical and Biophysical Research Communications, 2011, 407, 225-229.	2.1	16
46	Suppression of BMP-Smad Signaling Axis-Induced Osteoblastic Differentiation by Small C-terminal Domain Phosphatase 1, a Smad Phosphatase. Molecular Endocrinology, 2011, 25, 474-481.	3.7	27
47	Protein phosphatase magnesium-dependent 1A–mediated inhibition of BMP signaling is independent of Smad dephosphorylation. Journal of Bone and Mineral Research, 2010, 25, 653-660.	2.8	40
48	Deformity of the great toe in fibrodysplasia ossificans progressiva. Journal of Orthopaedic Science, 2010, 15, 804-809.	1.1	27
49	Dual Roles of Smad Proteins in the Conversion from Myoblasts to Osteoblastic Cells by Bone Morphogenetic Proteins. Journal of Biological Chemistry, 2010, 285, 15577-15586.	3.4	70
50	Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a GSK3β-dependent and β-catenin-independent mechanism. Differentiation, 2010, 80, 46-52.	1.9	49
51	Heterotopic Bone Formation Induced by Bone Morphogenetic Protein Signaling: Fibrodysplasia Ossificans Progressiva. Journal of Oral Biosciences, 2010, 52, 33-41.	2.2	24
52	Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva. Journal of Biological Chemistry, 2009, 284, 7149-7156.	3.4	184
53	DRAGON, a GPlâ€anchored membrane protein, inhibits BMP signaling in C2C12 myoblasts. Genes To Cells, 2009, 14, 695-702.	1.2	23
54	Bone morphogenetic protein-2 down-regulates miR-206 expression by blocking its maturation process. Biochemical and Biophysical Research Communications, 2009, 383, 125-129.	2.1	44

#	Article	IF	CITATIONS
55	The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. Journal of Clinical Investigation, 2009, 119, 3462-72.	8.2	178
56	Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). Journal of Bone and Mineral Metabolism, 2008, 26, 521-530.	2.7	73
57	BMP type I receptor inhibition reduces heterotopic ossification. Nature Medicine, 2008, 14, 1363-1369.	30.7	559
58	A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochemical and Biophysical Research Communications, 2008, 377, 905-909.	2.1	69
59	Platelet-rich plasma stimulates osteoblastic differentiation in the presence of BMPs. Biochemical and Biophysical Research Communications, 2007, 361, 62-67.	2.1	52
60	Establishment of a novel method for enriching osteoblast progenitors from adipose tissues using a difference in cell adhesive properties. Biochemical and Biophysical Research Communications, 2006, 343, 1118-1123.	2.1	17
61	Purification and identification of a BMP-like factor from bovine serum. Biochemical and Biophysical Research Communications, 2006, 345, 1224-1231.	2.1	72
62	Differentiation and Monitoring of Cells Using a Biochip for Regenerative Medicine. JSME International Journal Series C-Mechanical Systems Machine Elements and Manufacturing, 2006, 49, 852-858.	0.3	3
63	Heparin Potentiates the in Vivo Ectopic Bone Formation Induced by Bone Morphogenetic Protein-2. Journal of Biological Chemistry, 2006, 281, 23246-23253.	3.4	251
64	Sulfated Polysaccharides Enhance the Biological Activities of Bone Morphogenetic Proteins. Journal of Biological Chemistry, 2003, 278, 43229-43235.	3.4	239
65	Identification of a BMP-responsive element inId1, the gene for inhibition of myogenesis. Genes To Cells, 2002, 7, 949-960.	1.2	226
66	Expression of mouse osteocalcin transcripts, OG1 and OG2, is differently regulated in bone tissues and osteoblast cultures. Journal of Bone and Mineral Metabolism, 2001, 19, 345-351.	2.7	12
67	Skeletal abnormalities in doubly heterozygousBmp4 andBmp7 mice. Genesis, 1998, 22, 340-348.	2.1	113
68	A Kinase Domain-truncated Type I Receptor Blocks Bone Morphogenetic Protein-2-induced Signal Transduction in C2C12 Myoblasts. Journal of Biological Chemistry, 1997, 272, 22046-22052.	3.4	76
69	Smad1 and Smad5 Act Downstream of Intracellular Signalings of BMP-2 That Inhibits Myogenic Differentiation and Induces Osteoblast Differentiation in C2C12 Myoblasts. Biochemical and Biophysical Research Communications, 1997, 238, 574-580.	2.1	198
70	Bone Morphogenetic Protein-2 Inhibits Terminal Differentiation of Myogenic Cells by Suppressing the Transcriptional Activity of MyoD and Myogenin. Experimental Cell Research, 1997, 230, 342-351.	2.6	130
71	Constitutively Active BMP Type I Receptors Transduce BMP-2 Signals without the Ligand in C2C12 Myoblasts. Experimental Cell Research, 1997, 235, 362-369.	2.6	106
72	Bone morphogenetic protein-2 does not alter the differentiation pathway of committed progenitors of osteoblasts and chondroblasts. Cell and Tissue Research, 1996, 284, 9-17.	2.9	26

#	Article	IF	CITATIONS
73	The role of gravity in chick embryogenesis. FEBS Letters, 1994, 340, 34-38.	2.8	22
74	The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. Biochemical and Biophysical Research Communications, 1990, 172, 295-299.	2.1	477